GlobalData on MSN18h
J&J sues Samsung Bioepis over ‘surreptitious’ breach of Stelara biosimilar contract
Samsung Bioepis has now allegedly sub-licensed its Stelara biosimilar rights to a health conglomerate, breaching a previous ...
J&J suing Samsung Bioepis over Stelara biosimilar (update)
Johnson & Johnson (NYSE:JNJ) is suing Samsung Bioepis for breach of contract related to the launch of a biosimilar of J&J's ...
JD Supra21h
Biologics and Biosimilars Landscape 2024: IP, Policy, and Market Developments
Last year marked an all-time record of 18 Food and Drug Administration (FDA) biosimilar approvals, bringing the total number ...